[1] 张振沛, 李德海, 顾谦群, 栾业鹏. 选择性HDAC抑制剂的研究进展. 中国药物化学杂志, 2013, 23(4): 321-330. [2] Deng CC, Lipstein M, Rodriguez R, Jirau Serrano XO, McIntosh C, Tsai WY, Wasmuth AS, Jaken S, O'Connor OA. The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. Clin Cancer Res , 2015, 21(1): 134-145. [3] Lübbert M, Kuendgen A. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges. Cancer , 2015, 121(4): 498-501. [4] Chen XM, Xie XB, Zhao Q, Wang F, Bai Y, Yin JQ, Jiang H, Xie XL, Jia Q, Huang G. Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells. Mol Med Rep , 2015, 11(1): 105-112. [5] Shen Q, Tang WF, Sun J, Feng LF, Jin HC, Wang X. Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer. Am J Transl Res , 2014, 6(5): 538-547. [6] Zhu XJ, Liu J, Xu XY, Zhang CD, Dai DQ. The Pleckstrin and Sec7 domain-containing gene as a novel epigenetic modification marker in human gastric cancer and its clinical significance. Int J Oncol , 2015, 46(1): 195-204. [7] Li YL, Yang TS, Ruan WM, Cui W, Jin Y, Zou XM. Effect of trichostatin a on SGC-7901 gastric cancer cells. Int J Clin Exp Med , 2014, 7(8): 1958-1966. [8] Shi QQ, Zuo GW, Feng ZQ, Zhao LC, Luo L, You ZM, Li DY, Xia J, Li J, Chen DL. Effect of trichostatin A on anti HepG2 liver carcinoma cells: inhibition of HDAC activity and activation of Wnt/β-Catenin signaling. Asian Pac J Cancer Prev , 2014, 15(18): 7849-7855. [9] Yang XL, Zhang CD, Wu HY, Wu YH, Zhang YN, Qin MB, Wu H, Liu XC, Lina X, Lu SM. Effect of trichostatin A on CNE2 nasopharyngeal carcinoma cells-genome-wide DNA methylation alteration. Asian Pac J Cancer Prev , 2014, 15(11): 4663-4670. [10] Yang DH, Lee JW, Lee J, Moon EY. Dynamic rearrangement of F-actin is required to maintain the antitumor effect of trichostatin A. PLoS One , 2014, 9(5): e97352. [11] Peiffer L, Poll-Wolbeck SJ, Flamme H, Gehrke I, Hallek M, Kreuzer KA. Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. J Cancer Res Clin Oncol , 2014, 140(8): 1283-1293. [12] Xiong JJ, Xu XY, Zhou XO, Liu JY, Gong Z, Wu P, Li WD. USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A. Mol Med Rep , 2014, 10(6): 3343-3347. [13] Lee YH, Seo D, Choi KJ, Andersen JB, Won MA, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res , 2014, 74(17): 4752-4761. [14] Chittur SV, Sangster-Guity N, McCormick PJ. Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics , 2008, 9: 507. [15] Nunes MJ, Moutinho M, Gama MJ, Rodrigues CMP, Rodrigues E. Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux. PLoS One , 2013, 8(1): e53394. [16] Nunes MJ, Moutinho M, Milagre I, Gama MJ, Rodrigues E. Okadaic acid inhibits the trichostatin A-mediated increase of human CYP46A1 neuronal expression in a ERK1/2-Sp3-dependent pathway. J Lipid Res , 2012, 53(9): 1910-1919. [17] Milagre I, Nunes MJ, Moutinho M, Rivera I, Fuso A, Scarpa S, Gama MJ, Rodrigues E. Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination. J Alzheimers Dis , 2010, 22(4): 1209-1221. [18] Chittur SV, Sangster-Guity N, McCormick PJ. Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics , 2008, 9: 507. [19] Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res , 2013, 41(Web Server issue): W77-W83. [20] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA , 2005, 102(43): 15545-15550. [21] Motallebipour M, Enroth S, Punga T, Ameur A, Koch C, Dunham I, Komorowski J, Ericsson J, Wadelius C. Novel genes in cell cycle control and lipid metabolism with dynamically regulated binding sites for sterol regulatory element-binding protein 1 and RNA polymerase II in HepG2 cells detected by chromatin immunoprecipitation with microarray detection. FEBS J , 2009, 276(7): 1878-1890. [22] Tang XL, Deng LB, Xiong HG, Li GL, Lin JR, Liu SM, Xie JY, Liu J, Kong FJ, Tu GH, Peng HY, Liang SD. Expression profile of mitrogen-activated protein kinase (MAPK) signaling genes in the skeletal muscle & liver of rat with type 2 diabetes: role in disease pathology. Indian J Med Res , 2014, 140(6): 744-755. [23] Nunes MJ, Moutinho M, Gama MJ, Rodrigues CMP, Rodrigues E. Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux. PLoS One , 2013, 8(1): e53394. [24] Chittur SV, Sangster-Guity N, McCormick PJ. Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics , 2008, 9: 507. [25] Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol , 2005, 42(2): 210-217. [26] Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN. Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem , 2010, 285(19): 14663-14670. [27] Zhao SM, Xu W, Jiang WQ, Yu W, Lin Y, Zhang TF, Yao J, Zhou L, Zeng YX, Li H, Li YX, Shi J, An WL, Hancock SM, He FC, Qin LX, Chin J, Yang PY, Chen X, Lei QY, Xiong Y, Guan KL. Regulation of cellular metabolism by protein lysine acetylation. Science , 2010, 327(5968): 1000-1004. [28] Klootwijk ED, Reichold M, Helip-Wooley A, Tolaymat A, Broeker C, Robinette SL, Reinders J, Peindl D, Renner K, Eberhart K, Assmann N, Oefner PJ, Dettmer K, Sterner C, Schroeder J, Zorger N, Witzgall R, Reinhold SW, Stanescu HC, Bockenhauer D, Jaureguiberry G, Courtneidge H, Hall AM, Wijeyesekera AD, Holmes E, Nicholson JK, O'Brien K, Bernardini I, Krasnewich DM, Arcos-Burgos M, Izumi Y, Nonoguchi H, Jia YZ, Reddy JK, Ilyas M, Unwin RJ, Gahl WA, Warth R, Kleta R. Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med , 2014, 370(2): 129-138. [29] 冀堃. ALPL基因突变影响ADRB2基因调控BMMSCs成骨分化的实验研究[学位论文]. 第四军医大学, 2013. [30] 闻治国, 侯水生, 谢明, 黄苇. 肝脏极低密度脂蛋白合成和分泌的研究进展. 动物营养学报, 2011, 23(11): 1854-1861. [31] Tran K, Sun FC, Cui Z, Thorne-Tjomsland G, St Germain C, Lapierre LR, McLeod RS, Jamieson JC, Yao ZM. Attenuated secretion of very low density lipoproteins from McA-RH7777 cells treated with eicosapentaenoic acid is associated with impaired utilization of triacylglycerol synthesized via phospholipid remodeling. Biochim Biophys Acta , 2006, 1761(4): 463-473. |